Open Access<p>Biomarkers of IL-33 and sST2 and Lack of Association with Carvedilol Therapy in Heart Failure</p>
Author(s) -
Negar Firouzabadi,
Maryam Fadaie Dashti,
Ali Dehshahri,
Ehsan Bahramali
Publication year - 2020
Publication title -
clinical pharmacology
Language(s) - English
Resource type - Journals
ISSN - 1179-1438
DOI - 10.2147/cpaa.s256290
Subject(s) - carvedilol , medicine , heart failure , receptor , cardiology , endocrinology , pharmacology
The IL-33/ST2 pathway plays a fundamental role in the cardiovascular system and can be considered as a new therapeutic strategy for the treatment or prevention of cardiovascular diseases. ST2, as an interleukin (IL)-1 receptor family member, has transmembrane (ST2L) and soluble (sST2) isoforms. sST2 neutralizes IL-33 and thereby inhibits the cardioprotective role of IL-33/ST2L signaling pathway. Increase in sST2 level is associated with weak cardiac output and can be a predictor of mortality in heart failure (HF). Thereby, we hypothesized that there may be a relationship between the cardioprotective effects of carvedilol and sST2 and IL-3 in HF patients.